Skip to content
PatentBrief
Get alertsTop ↑

Targeting Cancer Cells with Smart, Internalizing Antibodies

This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.

ActiveExpires 2042Owned by Genmab ASInvented by Joost MELIS, Tom Vink, Esther BREIJ + 4 more

Original patent title: “Multispecific antigen-binding molecule with improved internalization characteristics”

Plain-English explanation by SahiLast reviewed · November 4, 2026

This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present. Owned by Genmab AS with 55 claims and 1 forward citation, and it is expected to expire in 2042.

Coverage

What does this patent actually cover?

This patent describes a special molecule, like an antibody, that has two specific parts, called antigen-binding domains. The first part is designed to attach to a 'target molecule (T)' often found on cancer cells (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1). The second part attaches to an 'internalizing effector protein (E)' (Claim 1), which is a protein on the cell surface that helps pull things inside. The key feature is that this second part has a very specific binding strength, or 'dissociation constant (KD),' for the effector protein (E), set between 10^-9 and 10^-8 M (Claim 1). This precise binding strength helps the entire molecule get pulled into the cell more efficiently, especially when the target molecule (T) is also present (Claim 8, 10). For example, a HER2xCD63 bispecific antibody (Claim 36) could be designed to deliver a drug inside HER2-positive cancer cells.

The gap

What does this patent NOT cover?

  • Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Multispecific antibodies where the second binding domain's affinity (KD) for the internalizing effector protein (E) is outside the specified 10^-9 to 10^-8 M range (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Molecules that internalize into cells without requiring the presence of the target molecule (T) for enhanced internalization (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 8).
  • Molecules where the effector protein (E) is not a cell surface molecule that is internalized into the cell (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 7).
  • Molecules where the target (T) is not associated with a tumor or cancer (AbstractabstractA short summary at the front of the patent describing the invention. Not legally binding.Read more →, ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 35).

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 20230076417
StatusActive
FieldBiotech & Medicine
AssigneeGenmab AS
InventorsJoost MELIS, Tom Vink, Esther BREIJ and 4 others
Filed2022
Expires2042
Claims55
Times cited1
LitigationNone on record
Value · $144K–$461KModest

What made this novel

The clever part is precisely defining the optimal binding strength (dissociation constant) for the second antigen-binding domain to an internalizing effector protein. This specific affinity range (10^-9 to 10^-8 M) is crucial for ensuring the molecule not only binds to the cell but also gets efficiently pulled inside and transported to the lysosomal compartment, especially when the cancer target is present (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1, 10). This fine-tuning enhances targeted delivery.

The Patent Drawing

Representative patent drawing for Multispecific antigen-binding molecule with improved internalization characteristics (US 20230076417)
Representative figure · US 20230076417All figures on Google Patents →
Multispecific antigen-binding …(Primary claim)biotechpharmaceuticaloncology

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Antibody-drug conjugates (ADCs) for cancer treatment

02

Bispecific antibodies designed to deliver drugs into tumor cells

03

HER2-targeting therapies that require cellular uptake

04

CD63-targeting therapies for enhanced internalization

Why it matters

The bigger picture

This technology aims to improve how therapeutic molecules, like drugs, are delivered into cancer cells. Many effective cancer treatments need to get inside the cell to work properly. By making the delivery process more efficient and specific to cancer cells, this approach could lead to more potent treatments with fewer side effects, potentially improving patient outcomes.

Filed

April 6, 2022

Market context

Who's building on this

Companies in this space

Genmab AS, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is a prominent company focused on developing innovative antibody therapeutics, including multispecific antibodies for cancer. Other major pharmaceutical and biotechnology companies, such as Amgen, Roche, and Johnson & Johnson, are also actively developing multispecific antibodies and antibody-drug conjugates, often exploring advanced delivery mechanisms to improve efficacy and target specificity in cancer treatment.

Market impact

This patent's technology could significantly advance the field of targeted cancer therapies, particularly antibody-drug conjugates and other internalizing therapeutics. By enabling more efficient and specific delivery of therapeutic agents into cancer cells, it could lead to the development of new drugs with improved efficacy and reduced systemic toxicity. This innovation has the potential to expand treatment options for various cancers and improve patient outcomes by making therapies more precise.

Claim 1 — Plain English

What this patent covers

This patent describes a special molecule, like an antibody, that has two specific parts, called antigen-binding domains. The first part is designed to attach to a 'target molecule (T)' often found on cancer cells (Claim 1). The second part attaches to an 'internalizing effector protein (E)' (Claim 1), which is a protein on the cell surface that helps pull things inside. The key feature is that this second part has a very specific binding strength, or 'dissociation constant (KD),' for the effector protein (E), set between 10^-9 and 10^-8 M (Claim 1). This precise binding strength helps the entire molecule get pulled into the cell more efficiently, especially when the target molecule (T) is also present (Claim 8, 10). For example, a HER2xCD63 bispecific antibody (Claim 36) could be designed to deliver a drug inside HER2-positive cancer cells.

The clever bit

The clever part is precisely defining the optimal binding strength (dissociation constant) for the second antigen-binding domain to an internalizing effector protein. This specific affinity range (10^-9 to 10^-8 M) is crucial for ensuring the molecule not only binds to the cell but also gets efficiently pulled inside and transported to the lysosomal compartment, especially when the cancer target is present (Claim 1, 10). This fine-tuning enhances targeted delivery.

What it does not cover

  • Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).
  • Multispecific antibodies where the second binding domain's affinity (KD) for the internalizing effector protein (E) is outside the specified 10^-9 to 10^-8 M range (Claim 1).
  • Molecules that internalize into cells without requiring the presence of the target molecule (T) for enhanced internalization (Claim 8).
  • Molecules where the effector protein (E) is not a cell surface molecule that is internalized into the cell (Claim 7).
  • Molecules where the target (T) is not associated with a tumor or cancer (Abstract, Claim 35).

Patent timeline

Filing

Application submitted to the patent office

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Moderate

Citation count

6/40

Early citations

Claim breadth

20/20

Very broad protection

Recency

0/20

Older than 20 years

Assignee scale

20/20

Major company or institution

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$144K – $461K

Midpoint $288K · 15.4 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

55 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

1

earlier patents this invention cites as foundations

View prior art →

Cited by later patents

1

later patents that build on this invention

View patents →

Cite this patent

MELIS, J., Vink, T., BREIJ, E., Parren, P., Goeij, B. D., NAPEL, H. T., & Satijn, D. Targeting Cancer Cells with Smart, Internalizing Antibodies (U.S. Patent No. 20,230,076,417). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20230076417/multispecific-antigen-binding-molecule-with-improved-internalization-characteris

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US20230076417"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →oncology patents →

Common Questions

Frequently Asked Questions

What does Targeting Cancer Cells with Smart, Internalizing Antibodies cover?

This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.

Who owns patent US 20230076417?

This patent is owned by Genmab AS.

When does this patent expire?

This patent is expected to expire on April 6, 2042, when the invention enters the public domain.

What is patent US 20230076417 cited by?

This patent has been cited by 1 later patents that build on its ideas.

What problem does this patent solve?

This technology aims to improve how therapeutic molecules, like drugs, are delivered into cancer cells. Many effective cancer treatments need to get inside the cell to work properly. By making the delivery process more efficient and specific to cancer cells, this approach could lead to more potent treatments with fewer side effects, potentially improving patient outcomes.

What does this patent NOT cover?

Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).

Patent monitoring

Get notified when Genmab AS files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 4, 2026 · PatentBrief is not a law firm and this is not legal advice.